Anduril IPO before 2027?

Prediction markets put the probability at 11%: Anduril IPO before 2027. Currently, markets see this as unlikely (11% YES). Polymarket launches private company trading so investors can speculate on Anthropic, OpenAI.

What’s Happening

The prediction market on Polymarket assessing whether defense technology company Anduril will complete an initial public offering before 2027 currently shows an 11% probability of a YES outcome, reflecting significant skepticism among traders. This market exists within a broader ecosystem of private company speculation on the platform, which recently expanded to include milestones for firms like OpenAI and Anthropic, as reported by CNBC on May 19, 2026. The low probability for Anduril contrasts sharply with the surging IPO pipeline for other high-profile private companies: SpaceX publicly filed its IPO prospectus on May 20, 2026, while OpenAI is preparing a confidential filing, and Oura Health also filed confidentially on May 21, 2026, according to Forbes. This wave of activity suggests that while the broader IPO market is heating up, Anduril’s timeline remains uncertain, with traders assigning a low probability to a pre-2027 listing. [CNBC, May 19]

The 89% NO probability on the Anduril IPO market reflects several structural factors. Anduril, a defense contractor specializing in autonomous systems and AI-powered surveillance, has historically prioritized government contracts over public market access, and its valuation—estimated at $14 billion after a 2024 funding round—remains below the threshold typically required for a blockbuster IPO. By comparison, SpaceX is targeting a valuation exceeding $200 billion in its upcoming listing, while OpenAI is reportedly seeking a valuation above $150 billion, according to Axios on May 20, 2026. The U.S. IPO market in 2026 is poised for a breakout year, with a strong pipeline of companies, but Anduril’s niche in defense—a sector with longer sales cycles and regulatory hurdles—may delay its public debut. The yield curve remains inverted as of late May, with the 2-year Treasury yield at 4.85% versus the 10-year at 4.52%, a signal that investors are pricing in economic uncertainty that could further dampen IPO appetite for smaller issuers. [Axios, May 20]

Looking ahead, the key catalyst for the Anduril IPO market would be a formal announcement of a confidential filing with the SEC, similar to moves by SpaceX and OpenAI. The May 20, 2026 filing by SpaceX, which includes its merger with xAI and X, has set a benchmark for defense-adjacent tech IPOs, but Anduril has not indicated any such plans. The Bureau of Labor Statistics reported on May 10, 2026 that the CPI rose 3.4% year-over-year in April, above the Fed’s 2% target, which could keep interest rates elevated and reduce the attractiveness of new listings. If Anduril does not file by mid-2027, the market will expire with a NO outcome, but a sudden shift in defense spending or a major contract win could alter the calculus. The Polymarket contract, which allows speculation on private company milestones, is part of a growing trend of using prediction markets to gauge IPO timing, as noted by CNBC. [Forbes

Traded on Polymarket — $352K Volume